Effects on Immune Cells of a New 1,8-Naphthyridin-2-One Derivative and Its Analogues as Selective CB2 Agonists: Implications in Multiple Sclerosis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Malfitano, Anna Maria ^a,b   Laezza, Chiara ^c   D'Alessandro, Alba ^a,b   Procaccini, Claudio ^b,c   Saccomanni, Giuseppe ^d   Tuccinardi, Tiziano ^d   Manera, Clementina ^d   Macchia, Marco ^d   Matarese, Giuseppe ^b,c   Gazzerro, Patrizia ^a   Bifulco, Maurizio ^a,b  

^a UNIVERSITY OF SALERNO   (Italy)

^b Dipartimento di Medicina e Chirurgia   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,8 NAPHTHYRIDINE 2 ONE DERIVATIVE; 1,8 NAPHTHYRIDINE DERIVATIVE; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N (4 METHYLCYCLOHEXYL) 1 BENZYL 1,8 NAPHTHYRIDIN 1(1H) ON 3 CARBOXAMIDE; N CYCLOHEPTHYL 1 (2 MORPHOLIN 4 YLETHYL) QUINOLIN 2(1H) ON 3 CARBOXAMIDE; N CYLOHEPTHYL 1 (4 FLUOROBENZYL) 1,2 DIHYDRO 2 OXO PYRIDINE 3 CARBOXAMIDE; PROTEIN KINASE B; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PHOSPHORYLATION;

ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; NAPHTHYRIDINES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; QUINOLONES; RECEPTOR, CANNABINOID, CB2; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877045028     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062511     Document Type: Article

References (31)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-4.
2. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmac Rev 54: 161-202.
3. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126 (Pt 10): 2191-202.
4. Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D, (2005) Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134 (1): 261-8.
5. Loría F, Petrosino S, Hernangómez M, Mestre L, Spagnolo A, et al. (2010) An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis. 37(1): 166-76.
6. Klein TW, Newton C, Larsen K, Lu L, Perkins, et al, (2003) The cannabinoid system and immune modulation. J Leukoc Biol. 74(4): 486-96.
7. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (5746): 329-32.
8. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, et al. (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13(4): 492-7.
9. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, et al. (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071 (1): 10-23.
10. Malfitano AM, Matarese G, Bifulco M, (2005) From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases. Curr Drug Targets CNS Neurol Disord 4(6): 667-75.
11. Bifulco M, Malfitano AM, Pisanti S, Laezza C, (2008) Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer. 15(2): 391-408.
12. Malfitano AM, Proto MC, Bifulco M, (2008) Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat 4(5): 847-53.
13. Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza, et al, (2011) Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets. 15(3): 297-308.
14. Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, et al. (2012) Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol. 227(1): 250.
15. Hillard CJ, Weinlander KM, Stuhr KL, (2012) Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience. 204: 207-29.
16. Bifulco M, Laezza C, Malfitano AM, (2007) From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Mult Scler 13(1): 133-4.
17. Sospedra M, Martin R, (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683-747.
18. Malfitano AM, Matarese G, Pisanti S, Grimaldi C, Laezza C, et al. (2006) Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J Neuroimmunol 171(1-2): 110-9.
19. Pertwee RG, (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156(3): 397-411.
20. Chuchawankul S, Shima M, Buckley NE, Hartmann CB, McCoy KL, (2004) Role of cannabinoid receptors in inhibiting macrophage costimulatory activity. Int Immunopharmacol 4(2): 265-78.
21. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, et al. (2008) The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 283(19): 13320-9.
22. Lombard C, Nagarkatti M, Nagarkatti P, (2007) CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 122(3): 259-70.
23. Manera C, Benetti V, Castelli MP, Cavallini T, Lazzarotti S, et al. (2006) Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J Med Chem 49(20): 5947-57.
24. Manera C, Saccomanni G, Adinolfi B, Benetti V, Ligresti A, et al. (2009) Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists. J Med Chem 52(12): 3644-51.
25. Ferrarini PL, Calderone V, Cavallini T, Manera C, Saccomanni G, et al. (2004) Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. Bioorg Med Chem 12: 1921-33.
26. Manera C, Cascio MG, Benetti V, Allarà M, Tuccinardi T, et al. (2007) New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett 17(23): 6505-10.
27. Manera C, Saccomanni G, Malfitano AM, Bertini S, Castelli F, et al. (2012) Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold. Eur J Med Chem 52: 284-94.
28. Benavides A, Napolitano A, Bassarello C, Carbone V, Gazzerro P, et al. (2009) Oxylipins from Dracontium loretense. J Nat Prod. 72(5): 813-7.
29. Malfitano AM, Toruner GA, Gazzerro P, Laezza C, Husain S, et al. (2007) Arvanil and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells. Immunol Lett. 109(2): 145-54.
30. Mestre L, Docagne F, Correa F, Loría F, Hernangómez M, et al. (2009) A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci. 40(2): 258-66.
31. Sun X, Wang X, Chen T, Li T, Cao K, et al. (2010) Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-dependent inflammatory response in murine system. PLoS One 5(2): e9380.